Advancing Diagnostics Through Digital Pathology and Genomics

Advances in genomics are transforming diagnostic pathways by adding a new molecular layer to what digital pathology can reveal. While digital pathology provides precise visual and morphological insights, genomic testing uncovers the underlying biological drivers of disease thus allowing clinicians to detect recurrence earlier, stratify risk more accurately, and personalise treatment with greater confidence. Together, these approaches create a more reliable, data-rich diagnostic ecosystem that improves patient outcomes while reducing unnecessary procedures.

Source LDPath and Source Genomics, both part of Source BioScience, combine leading digital pathology services with advanced molecular diagnostics to offer a comprehensive, integrated clinical testing solution. This unified approach ensures that clinicians receive both morphological and genomic insights through a single, streamlined pathway.

Following the acquisition of Cambridge Clinical Laboratories (CCL), Source BioScience has expanded its clinical test portfolio, introducing a broader range of advanced diagnostic options.

An overview of the newly available tests is outlined below:

Proclarix – Risk Stratification in Prostate Cancer

Proclarix is a blood test that refines risk assessment in men with borderline PSA levels (2–10 ng/mL). By combining protein biomarkers with clinical variables, it delivers an individualised risk score that reduces unnecessary biopsies while maintaining confidence in detecting significant cancer. It improves diagnostic decision-making and streamlines referral pathways.

MAF Test – Bone Metastasis Risk in Breast Cancer

The MAF Test identifies MAF gene amplification in tumour tissue to predict risk of bone metastasis in early breast cancer. It guides personalised use of bisphosphonates, ensuring patients receive therapies that are effective for their genomic profile. This enables more precise treatment planning and avoids potentially harmful interventions.

EpiCheck® – Bladder Cancer Recurrence Monitoring

EpiCheck is a non-invasive urine test that detects DNA methylation markers linked to bladder cancer. With its high negative predictive value, it safely extends cystoscopy intervals and identifies patients who need timely investigation. It supports clinicians in long-term surveillance of NMIBC by reducing unnecessary invasive procedures.

EarlyCDT Lung – Risk Assessment for Indeterminate Pulmonary Nodules

EarlyCDT Lung measures autoantibodies linked to lung cancer to reclassify risk in indeterminate pulmonary nodules. A positive result significantly increases malignancy likelihood, helping distinguish nodules needing intervention from those suitable for surveillance. It supports earlier diagnosis and reduces unnecessary invasive procedures.